Adicet Bio (ACET) has released an update to notify the public and investors about an entry into a material definitive agreement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adicet Bio, Inc. entered into an agreement with Jefferies LLC and Guggenheim Securities, LLC for an underwritten public offering of over 27 million shares of common stock and pre-funded warrants for additional shares. The shares and pre-funded warrants were offered publicly at $2.40 and $2.3999 respectively, with the underwriters purchasing at a 6% discount. The underwriters also exercised their option to purchase an additional 5.325 million shares. The offering, expected to close on January 25, 2024, is estimated to net the Company approximately $91.8 million, with additional potential proceeds from warrant exercises, subject to ownership limitations and adjustments.
For further insights into ACET stock, check out TipRanks’ Stock Analysis page.